Literature DB >> 24453029

Association between a functional insertion/deletion polymorphism in IL1A gene and risk of papillary thyroid carcinoma.

Linbo Gao1, Xinxin Zhu, Zhihui Li, Lijuan Li, Tao Wang, Huaizhong Hu, Wanli Guo, Peng Chen, Jingqiang Zhu, Lin Zhang.   

Abstract

The aim of this study was to evaluate whether an insertion/deletion polymorphism (rs3783553) locating in the miR-122 target gene IL1A 3' untranslated region was related to the risk of papillary thyroid carcinoma (PTC). Genomic DNA was extracted from peripheral venous blood of 273 patients with PTC and 509 controls. The IL1A rs3783553 polymorphism was genotyped by using a polymerase chain reaction assay. No significant difference of the distribution of the IL1A rs3783553 polymorphism was observed between PTC patients and controls. However, patients carrying the IL1A rs3783553 ins/ins genotype and ins allele had significantly decreased risks for developing T3 and T4 when compared with patients carrying the IL1A rs3783553 del/del genotype and del allele (ins/ins vs. del/del: OR = 0.22, 95% confidence interval (CI), 0.09-0.54; ins vs. del: OR = 0.58, 95% CI, 0.41-0.83, respectively). These results suggest that the rs3783553 polymorphism may be used as a genetic marker to predict the size/extension of PTC.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24453029     DOI: 10.1007/s13277-013-1512-6

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  28 in total

1.  A let-7 binding site polymorphism rs712 in the KRAS 3' UTR is associated with an increased risk of gastric cancer.

Authors:  Zhao-Hui Li; Xin-Min Pan; Bao-Wei Han; Xiao-Min Guo; Zhen Zhang; Jing Jia; Lin-Bo Gao
Journal:  Tumour Biol       Date:  2013-06-02

2.  A functional polymorphism in IL-1A gene is associated with a reduced risk of gastric cancer.

Authors:  Xiao-Feng Zeng; Juan Li; Sheng-Bin Li
Journal:  Tumour Biol       Date:  2013-07-31

3.  IL-1β a potential factor for discriminating between thyroid carcinoma and atrophic thyroiditis.

Authors:  Maha Kammoun-Krichen; Noura Bougacha-Elleuch; Mouna Mnif; Fadia Bougacha; Ilhem Charffedine; Sandra Rebuffat; Ahmed Rebai; Emilie Glasson; Mohamed Abid; Fatma Ayadi; Sylvie Péraldi-Roux; Hammadi Ayadi
Journal:  Eur Cytokine Netw       Date:  2012 Jul-Sep       Impact factor: 2.737

4.  Increasing incidence of thyroid cancer in the United States, 1973-2002.

Authors:  Louise Davies; H Gilbert Welch
Journal:  JAMA       Date:  2006-05-10       Impact factor: 56.272

Review 5.  Papillary thyroid microcarcinoma: a surgical perspective.

Authors:  George H Sakorafas; John Giotakis; Vania Stafyla
Journal:  Cancer Treat Rev       Date:  2005-07-06       Impact factor: 12.111

6.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

7.  Association of IL-1 polymorphisms and IL-1 serum levels with susceptibility to nasopharyngeal carcinoma.

Authors:  Zhi-Hui Yang; Qiong Dai; Li Zhong; Xu Zhang; Qing-Xi Guo; Shi-Ning Li
Journal:  Mol Carcinog       Date:  2010-12-10       Impact factor: 4.784

8.  Interleukin-1alpha regulates G1 cell cycle progression and arrest in thyroid carcinoma cell lines NIM1 and NPA.

Authors:  K Zeki; I Morimoto; T Arao; S Eto; U Yamashita
Journal:  J Endocrinol       Date:  1999-01       Impact factor: 4.286

9.  Polymorphisms within micro-RNA-binding sites and risk of sporadic colorectal cancer.

Authors:  Debora Landi; Federica Gemignani; Alessio Naccarati; Barbara Pardini; Pavel Vodicka; Ludmila Vodickova; Jan Novotny; Asta Försti; Kari Hemminki; Federico Canzian; Stefano Landi
Journal:  Carcinogenesis       Date:  2008-01-12       Impact factor: 4.944

10.  Stimulatory effect of interleukin-1 alpha on proliferation through a Ca2+/calmodulin-dependent pathway of a human thyroid carcinoma cell line, NIM 1.

Authors:  N Inokuchi; K Zeki; I Morimoto; Y Nakano; T Fujihira; U Yamashita; N Yanagihara; F Izumi; S Eto
Journal:  Jpn J Cancer Res       Date:  1995-07
View more
  7 in total

1.  Association between a functional polymorphism rs712 within let-7-binding site and risk of papillary thyroid cancer.

Authors:  Hong Jin; Yundan Liang; Xunli Wang; Jingqiang Zhu; Ruifen Sun; Peng Chen; Xinwen Nie; Linbo Gao; Lin Zhang
Journal:  Med Oncol       Date:  2014-09-09       Impact factor: 3.064

2.  A functional variant at miRNA-122 binding site in IL-1α 3' UTR predicts risk and HPV-positive tumours of oropharyngeal cancer.

Authors:  Yang Zhang; Erich M Sturgis; Yan Sun; Chuanzheng Sun; Qingyi Wei; Zhigang Huang; Guojun Li
Journal:  Eur J Cancer       Date:  2015-05-14       Impact factor: 9.162

3.  Distribution of cytokine gene single nucleotide polymorphisms among a multi-ethnic Iranian population.

Authors:  Zana Karimi Kurdistani; Samaneh Saberi; Yeganeh Talebkhan; Akbar Oghalaie; Maryam Esmaeili; Nazanin Mohajerani; Maryam Bababeik; Parisa Hassanpour; Shaghik Barani; Ameneh Farjaddoost; Fatemeh Ebrahimzadeh; Jean Trejaut; Marjan Mohammadi
Journal:  Adv Biomed Res       Date:  2015-07-31

4.  Association between an insertion/deletion polymorphism in IL-1A gene and cancer risk: a meta-analysis.

Authors:  Ling Ma; Ning Zhou
Journal:  Onco Targets Ther       Date:  2015-12-18       Impact factor: 4.147

5.  Functional polymorphism rs3783553 in the 3'-untranslated region of IL-1A increased the risk of ischemic stroke: A case-control study.

Authors:  Peng Wang; Qian He; Chen Liu; Shi Zhen He; Shou Yan Zhu; Ying Wen Li; Wei Su; Shu Tian Xiang; Bo Zhao
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.889

6.  Integrated Analysis of Thyroid Cancer Public Datasets Reveals Role of Post-Transcriptional Regulation on Tumor Progression by Targeting of Immune System Mediators.

Authors:  Murilo V Geraldo; Edna T Kimura
Journal:  PLoS One       Date:  2015-11-04       Impact factor: 3.240

7.  A functional variant at miRNA-122 binding site in IL-1a 3' UTR predicts risk of recurrence in patients with oropharyngeal cancer.

Authors:  Chengyuan Wang; Erich M Sturgis; Xingming Chen; Qingyi Wei; Guojun Li
Journal:  Oncotarget       Date:  2016-06-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.